Ovidiu Dugulan/iStock
(NEW YORK) When Katharine Lee, a postdoctoral research fellow at Washington University in St. Louis, and Kathryn Clancy, an associate professor of anthropology at the University of Illinois Urbana-Champaign, each say they experienced unexpected menstrual cycles after receiving the COVID-19 vaccine, they did what researchers do and began to collect data.
Clancy conferred with Lee, who said several colleagues had also reported differing menstrual symptoms, and issued a single tweet in late February explaining her own symptoms and asking if anyone else had experienced anything similar.
Three months later, Lee and Clancy say more than 80,000 people have documented their experiences in an online survey they collaborated on examining short-term vaccine side effects related to the menstrual cycle.
RWE Alliance aims to boost policies and practices around real-world evidence healthcareitnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcareitnews.com Daily Mail and Mail on Sunday newspapers.
COVID-19 puts spotlight on disparities in research on women s health
• 19 min read
What to know about infertility and COVID-19 vaccines
Dr. Jennifer Ashton discusses how vaccines have not been proven to impact fertility and why women who are currently pregnant may want to get vaccinated.Frederic J. Brown/AFP via Getty Images
When Katharine Lee, a postdoctoral research fellow at Washington University in St. Louis, and Kathryn Clancy, an associate professor of anthropology at the University of Illinois Urbana-Champaign, each say they experienced unexpected menstrual cycles after receiving the COVID-19 vaccine, they did what researchers do and began to collect data.
The pandemic brought addiction recovery online What comes next? politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
First published on
Dive Brief:
CMS has delayed implementation of its contentious breakthrough payment rule until December 15, depriving the medtech industry, at least for now, of a policy once hailed as a significant tailwind.
The Medicare Coverage of Innovative Technology initiative would give breakthrough devices Medicare reimbursement automatically on the day they are approved or cleared by FDA.
Medtech manufacturers pushed for MCIT but high-profile detractors such as health insurance lobby America s Health Insurance Plans, as well as some doctor groups, drove CMS to delay implementation. The agency said it shares concerns that MCIT could be problematic in ensuring these devices are demonstrating value and do not have additional risks for Medicare beneficiaries.